New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open – Cancer Horizons" Series. (12th June 2019) - Lambertini, Matteo; Preusser, Matthias; Zielinski, Christoph C